Theregen Overview

  • Year Founded
  • 2003

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Theregen General Information

Description

Developer of cell-based therapies designed to address cardiovascular diseases. The company's epicardial patch Anginera induces formation of mature blood vessels in the human myocardium, enabling physicians to address ischemia and induce arteriogenesis in patients.

Contact Information

Formerly Known As
IKEN Tissue Therapeutics
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 225 Bush Street
  • Floor 16
  • San Francisco, CA 94104
  • United States
+1 (415)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 225 Bush Street
  • Floor 16
  • San Francisco, CA 94104
  • United States
+1 (415)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Theregen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 01-Dec-2016 Completed Out of Business
3. Early Stage VC 07-Feb-2006 Completed Startup
2. Early Stage VC (Series A1) 17-Jan-2006 $1.5M $3.27M Completed Startup
1. Early Stage VC (Series A) 08-Nov-2005 $1.77M $1.77M Completed Startup
To view Theregen’s complete valuation and funding history, request access »

Theregen Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A1
Series A
To view Theregen’s complete cap table history, request access »

Theregen Patents

Theregen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2013049693-A Method for treating ischemic tissue Pending 17-Jun-2005
US-20060292125-A1 Using stem cell culture to treat/repair damage associated with cardiovascular event; tissue engineering; regenerative medicine Inactive 17-Jun-2005
US-20060140916-A1 Methods and compositions for treating congestive heart failure Inactive 22-Nov-2004
US-20090317482-A1 Methods and compositions for treating congestive heart failure Inactive 22-Nov-2004
US-20110212068-A1 Methods and compositions for treating congestive heart failure Inactive 22-Nov-2004 A61K35/34
To view Theregen’s complete patent history, request access »

Theregen FAQs

  • When was Theregen founded?

    Theregen was founded in 2003.

  • Where is Theregen headquartered?

    Theregen is headquartered in San Francisco, CA.

  • What industry is Theregen in?

    Theregen’s primary industry is Biotechnology.

  • Is Theregen a private or public company?

    Theregen is a Private company.

  • What is Theregen’s current revenue?

    The current revenue for Theregen is .

  • How much funding has Theregen raised over time?

    Theregen has raised $3.27M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process